How To Handle Off-Label Promotion: A Guide From PhRMA And BIO
Executive Summary
Industry communication principles offer best practices for combating contrary evidence, refuting third-party comparative effectiveness analyses and sharing real-world evidence addressing health outcomes and costs.
You may also be interested in...
BIO Lays Ethical Foundation For Change In Off-Label Communications
The industry group's future advocacy around legal and regulatory reforms affecting product sponsor communications with payers and health-care providers will align with four bioethical considerations.
Off-Label Communications: BIO Lays Ethical Foundation For Change
Industry group's future advocacy around legal and regulatory reforms affecting product sponsor communications with payers and health care providers will align with four bioethical considerations.
PhRMA/BIO Devise 'Principles' To End Off-Label Limbo
Tired of waiting for safe harbor protections about communicating to payers and prescribers about pharmacoeconomics and unapproved uses, PhRMA and BIO are trying to move discussion forward.